PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1708377
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1708377
Global External Ventricular Drain Market is estimated to be valued at USD 6.9 Bn in 2025 and is expected to reach USD 10.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 6.9 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 5.80% | 2032 Value Projection: | USD 10.24 Bn |
An external ventricular drain (EVD) is a soft catheter that is inserted via a burr hole into the anterior horn of the lateral ventricle and connected to a closed sterile system to allow for temporary drainage of cerebrospinal fluid (CSF) and/or monitoring of intracranial pressure. Indications for external ventricular drainage are: to relieve raised intracranial pressure, to divert infected CSF, to divert bloodstained CSF following neurosurgery/haemorrhage, to divert the flow of CSF, and to monitor intracranial pressure. External drainage and monitoring is the standard of care for temporarily controlling intracranial pressure by draining cerebrospinal fluid externally from the body. External drainage and monitoring is the temporary drainage of cerebrospinal fluid (CSF) from the lateral ventricles of the brain, or the lumbar space of the spine, into an external collection bag. An external ventricular drainage (EVD) system drains CSF by using a combination of gravity and intercerebral pressure. The drainage rate depends on the height at which the EVD system is placed relative to the patient's anatomy.
Increasing research and development (R&D) activities is expected to drive the growth of the global external ventricular drain market over the forecast period. For instance, in June 2024, Karolinska University Hospital, a hospital based in Sweden, initiated a clinical trial titled "Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections". This study will evaluate three novel diagnostic methods for rapid direct bacterial detection in CSF, in order to assess, if these can be used to guide antibiotic treatment in neurocritically ill patients, as compared to CSF bacterial cultures. The study is expected to get completed by December 31, 2025.